Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

43.64USD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$43.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,335,343
52-wk High
$45.25
52-wk Low
$20.08

AKRX.O

Chart for AKRX.O

About

Akorn, Inc. (Akom) is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, through its subsidiary Advanced Vision Research, Inc. (AVR), it manufactures and markets a line of over-the-counter (OTC) ophthalmic... (more)

Overall

Beta: 0.35
Market Cap (Mil.): $4,544.40
Shares Outstanding (Mil.): 104.13
Dividend: --
Yield (%): --

Financials

  AKRX.O Industry Sector
P/E (TTM): 105.89 33.49 34.41
EPS (TTM): 0.41 -- --
ROI: 6.49 18.10 17.37
ROE: 18.33 18.76 18.18
Search Stocks

Deals of the day- Mergers and acquisitions

(Updates EMC; Adds Akorn, Comcast, Grupos Salinas, Lucchini, Dentsu Aegis, Slovenske Elektrarne, Enel, BauMax, Verizon, Wind, BSkyB, Allergan, Hapag-Lloyd, Douglas, Eastman Chemical and Vodafone)

11 Sep 2014

Exclusive: Akorn eyes $2 billion UCB unit in potential tax inversion - sources

NEW YORK - U.S. specialty drugmaker Akorn Inc is exploring a bid for Belgian drugmaker UCB SA's U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar with the matter.

11 Sep 2014

Akorn wins U.S. approval to buy VersaPharm

WASHINGTON - Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic tuberculosis drug, the Federal Trade Commission said on Monday.

04 Aug 2014

Akorn wins U.S. approval to buy VersaPharm

WASHINGTON, Aug 4 - Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic tuberculosis drug, the Federal Trade Commission said on Monday.

04 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks